Perampanel as adjunctive therapy in drug resistant epilepsy in adolescents and children waiting for epilepsy surgery: A multicenter observational study in Thailand. (August 2022)

• Record Type: Journal Article
• Authors: Suwanpakdee, Piradee; Saksritavee, Burachat; Likasitthananon, Napakjira; Simasathien, Thitiwan; Deesudchit, Tayard; Khongkhatithum, Chaiyos; Viravan, Sorawit; Nabangchang, Charcrin
• Is Part Of: Seizure. Volume 100(2022)
• Page Start: 103
• Page End: 108
• Publication Date: 2022-08
• Subjects: Perampanel -- Anti-seizure medication -- Drug-resistant -- Treatment-resistant -- Epilepsy; Epilepsy -- Periodicals; Epilepsy -- Periodicals; Seizures -- Periodicals; Épilepsie -- Périodiques; Electronic journals; Electronic journals; 616.853
• DOI: 10.1016/j.seizure.2022.06.015
• Languages: English
• ISSNs: 1059-1311

Abstract

Abstract: Purpose: To evaluate the effectiveness and tolerability of perampanel (PER) in real-world settings in patients between 1 month and 18 years of age with drug resistant epilepsy (DRE) waiting for epilepsy surgery. Methods: In this multicenter study, patients between 1 month and 18 years of age with DRE treated with PER between January 2020 and June 2021 were selected. The study outcome was effectiveness of PER treatment reported as reduction in seizure frequency and seizure freedom rate. Effectiveness was assessed at 30, 60, 90, 120, 150 and 180 days after initiation of PER. Tolerability profiles were reported as adverse events according to the observations of the patients' family members and physician. Results: Eighty-five patients treated with PER were included in the study. The mean initial dose and mean maximum dose of adjunctive PER was 2 mg/day and 5.8 mg/day, respectively. The mean seizure frequency (rate/week) was 41.3, 25.4, 18.9, 14.3, 11.2, 11.1 and 8.9 seizures at baseline, 30, 60, 90, 120, 150 and 180 days, respectively; the reduction in the mean seizure frequency at all timepoints was significant compared at the baseline (p<0.001). At 180 days, ≥75% seizure reduction was seen in 64.9% (37/57) of the patients and seizure freedom was achieved in 36.8% (21/57). Drowsiness, ataxia, and behavioral changes were the common adverse events observed, and these improved after the dose of PER was reduced. No discontinuation of PER was required due to side effects or intolerance. Conclusion: In real-world settings, PER is well tolerated and effective in seizure control in pediatric and adolescent patients with DRE.